CAR-T cell and bispecific antibody (bsAB) therapies are a new option for adults with aggressive lymphoma or plasma cell diseases such as multiple myeloma that could not be cured with less intensive approaches, but little is known about their short- and long-term side effects in older people. This study investigates whether a pragmatic geriatric assessment performed before treatment can help predict side effects and outcomes. It enrolls patients aged 65 or older who are scheduled for CAR-T or bsAB treatment, can give informed consent, and have sufficient knowledge of German or French.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * male or female patients age ≥ 65 years, * scheduled for CAR-T-cell or bsAB treatments * signed informed consent * sufficient knowledge of the German or French language Exclusion Criteria: * inability to understand or sign informed consent * refuse to consent